The Future Is Non-Hormonal: Contraceptive Market Crawls Into The 21st Century
Early Stage Contraceptive Competitors Are Working On Hormone-Free Solutions
Executive Summary
Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.
You may also be interested in...
Finance Watch: Biopharma Reckoning Brings Restructuring Plans, Consolidation
With cash preservation in mind, Rubius will dissolve, while EQRx, Impel, Cybin and Graphite cut jobs. Meanwhile, Jounce is restructuring and it plans to merge with Redx, yet the dually troubled firms MEI Pharma and Infinity will combine, while VBL will disappear in a reverse merger with Notable Labs.
Dobbs Decision Could Have Knock-On Effects For Wider Reproductive Healthcare Landscape
The US Supreme Court’s overturning of Roe v. Wade, which enshrined the right to an abortion in the Constitution for almost 50 years, could have consequences that extend beyond access to termination of pregnancy.
Glucagon And Epinephrine Continue To Drive Growth At Amphastar
Amphastar has delivered another successful quarter, bolstered by sales of glucagon and epinephrine, as it prepares to roll out a number of commercially attractive products and complete a significant branded product acquisition.